← Back

Femasys Inc

Femasys Inc. is a biomedical company that develops and commercializes therapeutic and diagnostic products for women's reproductive health in the United States and internationally. Its offerings include FemaSeed, an intratubal insemination device; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemSperm, a sperm handling kit; FemChec, a tubal patency confirmation test; FemCerv, an endocervical tissue sampler for cervical cancer diagnosis; and FemCath, a cornual balloon catheter for selective tube evaluation. The company also provides FemBloc, a non-surgical permanent female birth control solution. Femasys serves gynecological physicians, related healthcare professionals, and women's healthcare provider organizations. Incorporated in 2004, it is headquartered in Suwanee, Georgia.

Country
Price · split & dividend adjusted
News & notes moving FEMY
FEMY▼

Femasys enters $30 million private placement with up to $90 million potential proceeds

Femasys Inc. has entered into a securities purchase agreement for a $30 million private placement of shares and warrants led by Nantahala Capital. The company is selling 9.37 million shares of common stock and prefunded warrants, along with accompanying warrants to purchase up to 18.75 million shares, at $3.20 per share and accompanying warrants or $3.1999 per prefunded warrant and accompanying warrants. The accompanying warrants have an exercise price of $2.95 per share, and upon full cash exercise, Femasys could receive up to an additional $60 million, bringing total potential proceeds to $90 million. The financing is expected to close on or around August 10, 2026, and will support the company's fertility portfolio launch to U.S. OB/GYNs and the advancement of its FemBloc clinical program. Femasys stock closed Friday at $2.66, down 10.74%, and fell a further 3.76% in after-hours trading.
FEMY ▼
RTTNews·39dRead more →
FEMY▲

Femasys Regains Nasdaq Compliance, Continues Reproductive Health Pipeline Push

Femasys has regained compliance with Nasdaq's minimum bid price requirement, securing its continued listing. CEO Kathy Lee-Sepsick called the milestone important for the company and its shareholders, emphasizing the focus on advancing strategic priorities and expanding access to reproductive health solutions. The company is commercializing a portfolio of fertility and permanent birth control products, including FemaSeed Intratubal Insemination, which has shown more than double the pregnancy rate of traditional intrauterine insemination in published clinical data, as well as FemVue, FemHSG Catheter, and FemBloc, the first non-surgical, in-office permanent birth control alternative that has received regulatory approvals in Europe, the UK, and New Zealand. Enrollment is ongoing in the pivotal FINALE trial for FemBloc to seek U.S. FDA approval. The stock closed Wednesday at $3.67, down 8.48%, and was at $3.65 in after-hours trading.
FEMY ▲
RTTNews·85dRead more →
© 2026 MarketDXAsset